AOD-9604: mechanism, evidence and research limits

AOD-9604 is a synthetic peptide analogue of the C-terminal region of human growth hormone (hGH): hGH residues 177–191 with an extra N-terminal tyrosine. It is therefore a peptide fragment/analogue, not full-length growth hormone, a small molecule, a topical cosmetic ingredient by definition, or an approved generic ‘research vial’ product.

AOD-9604 is a modified fragment of growth hormone, not full-length HGH. Early mouse experiments examined body-weight and fat-metabolism measures, but those model-specific findings do not establish clinical weight-loss benefit or the safety of an online research vial. This review separates its chemistry, trial history and Australian regulatory context.

AOD-9604 is commonly described as a ‘fat-loss peptide’, but that shorthand hides an important distinction. Analytical work defines it as the C-terminal hGH 177–191 fragment with an added tyrosine at the N-terminus; it is not the 191-amino-acid growth hormone molecule. The additional tyrosine means it is an analogue rather than a naturally cleaved, unchanged human fragment. In the same laboratory study, the parent peptide was degraded in serum and urine incubations into smaller peptides, which is relevant to testing and to the uncertainty around exposure from unapproved formulations. [1]

Its development history is as a prospective anti-obesity drug. A 2004 sponsor announcement described it as a small orally active peptide modelled on part of hGH, while a later regulator review records that the obesity development program was terminated after the larger OPTIONS trial did not show significant placebo-adjusted weight loss. This is a human research candidate with a discontinued obesity program, not a nutritional supplement and not an interchangeable version of prescribed hGH. [4] [5]

The foundational findings are in rodents, not people. In a 14-day experiment, obese ob/ob and lean C57BL/6J mice received AOD-9604, hGH or saline through mini-osmotic pumps. In the obese mice, AOD-9604 reduced body-weight gain and was associated with greater fat oxidation and higher plasma glycerol, a marker consistent with lipolysis. Unlike hGH in that study, it did not cause hyperglycaemia or reduced insulin secretion. The study does not establish that the same effects, magnitude or safety profile occur in humans with obesity. [2]

A separate mouse experiment used 14 days of intraperitoneal treatment in obese mice and beta-3 adrenergic receptor (β3-AR) knockout mice. AOD-9604 treatment in obese wild-type mice was associated with reduced body weight and fat and higher adipose β3-AR RNA. In the knockout model, chronic treatment did not produce the body-weight and lipolysis changes seen in wild-type controls, although an acute experiment still increased energy expenditure and fat oxidation. The authors concluded that the lipolytic action was not directly mediated through β3-AR, while increased receptor expression could contribute to later lipolytic sensitivity. [3]

These are useful mechanistic leads, but they are model-specific observations. Ob/ob mice, diet- and strain-dependent physiology, continuous pump exposure, intraperitoneal administration and genetic receptor deletion are not a substitute for an adequately reported clinical efficacy trial. The FDA’s later review likewise considered the molecular target unknown and the nonclinical evidence insufficient to inform safety for proposed human routes. [2] [3] [5]

AOD-9604 did not compete for the hGH receptor or induce proliferation in hGH-receptor-transfected cells in the 2001 mouse/cell study. That result is evidence against simply equating AOD-9604 with conventional hGH receptor signalling; it does not identify an alternative human receptor or prove that it has no endocrine effects in every setting. [2]

The β3-AR knockout experiment provides a plausible link between chronic treatment and adrenergic lipolytic sensitivity in mice, not proof that β3-AR is the direct molecular target. The FDA’s assessment explicitly describes the mechanism as unknown and unlikely to involve growth-hormone receptors, while noting dependence at least in part on intact β3-adrenergic signalling in rodent data. Claims that AOD-9604 has a known, selective ‘fat-cell receptor’ are stronger than the cited evidence supports. [3] [5]

The pivotal historical study was the sponsor’s OPTIONS trial: 536 adults with obesity were enrolled and 502 were randomised in a double-blind, placebo-controlled Australian study. After a four-week single-blind placebo run-in with dietitian-supervised diet and exercise, participants received oral placebo or 0.25 mg, 0.5 mg or 1 mg AOD-9604 once daily for 24 weeks. Its efficacy primary endpoint was statistically significant weight loss after 12 weeks versus placebo; the study was powered to detect a 1.8 kg placebo-adjusted difference. This describes a research protocol, not a current administration recommendation. [4]

The primary weight-loss endpoint was not met: the sponsor reported no significant difference between groups, and its secondary endpoints had no relevant findings. The company described a post-hoc-looking subgroup observation in women who had lost less than 2 kg during the run-in, but the pre-specified overall result remains negative. The FDA’s later review reached the same bottom line: the 536-person study did not find significant placebo-adjusted weight loss and the obesity program was terminated. [4] [5]

An earlier 12-week sponsor study randomised 300 adults with obesity to oral placebo or several doses and set body weight and CT-measured fat reduction as primary efficacy aims. A subsequent safety paper and the FDA briefing report a small mean weekly weight-loss difference in the available abstract-level account, with the largest reported effect at 1 mg/day. However, the FDA noted that the data were minimal, methods and results were insufficiently detailed, and the apparent clinical importance of the small difference was unclear. It should not outweigh the later, larger negative OPTIONS study. [6] [5] [10]

A 2013 article summarised six sponsor-funded randomised, double-blind, placebo-controlled studies, including oral studies lasting up to 24 weeks. It reported no statistically significant treatment-group differences in IGF-1, glucose-tolerance measures, routine laboratory results, vital signs or ECGs, and no anti-AOD-9604 antibodies in selected oral-study participants. In the 24-week study, adverse events were common across all groups, with headache, infections, musculoskeletal complaints and gastrointestinal events among the commonly reported categories; serious adverse events were distributed similarly among groups according to the authors. [6]

Those findings are reassuring only within their narrow evidentiary frame. The safety paper is a retrospective summary rather than a full, independently reported trial dataset, and the FDA flagged missing breakdowns of adverse events, interventions and outcomes, selected rather than universal antibody testing, and short study duration. The FDA also described nonclinical signals—including changes in lymphocytes, creatinine, triglycerides and liver-cell vacuolation in particular animal studies—but noted that underlying data were unavailable or limited. Neither source establishes safety for chronic, injected, high-dose, topical or combined use. [5] [6]

A recent FDA compounding review also warns that compounded AOD-9604 may pose immunogenicity risk for some routes and presents peptide-related impurity and active-ingredient-characterisation challenges. It states that available safety information is absent or limited and that serious adverse events have been identified as possibly associated, although causality is unclear. This is a regulator’s risk assessment, not evidence that every reported event was caused by the peptide. [10]

The current Australian Poisons Standard is the national scheduling instrument used for inclusion in state and territory legislation. It lists AOD-9604 (CAS 221231-10-3) in Schedule 4, whose heading is ‘Prescription only medicines and prescription animal remedies’. The 2015 scheduling decision also placed AOD-9604 in Appendix D, item 5, a category for which possession without authority is illegal under the model provisions. State and territory law gives the practical legal effect, so this is not personalised legal advice. [7] [8]

Scheduling controls availability; it does not demonstrate that an AOD-9604 product has been evaluated and registered for quality, safety and efficacy. In a 2026 court statement about advertisements, the TGA identified AOD9604 cream and injection among goods not entered in the ARTG during the relevant advertising period. The TGA separately warns that imported unapproved peptide products are often poorly labelled, may be powders or injectables in unmarked vials, and may lack verifiable contents, sterility or concentration. A vial’s label, a ‘research use’ disclaimer, or a claimed certificate of analysis is not equivalent to an ARTG-registered medicine. [12] [8]

For athletes, the status is clearer: the 2026 WADA Prohibited List names AOD-9604 under growth-hormone fragments prohibited at all times. WADA had earlier stated that it had no therapeutic approval by any government health authority and therefore fell under its non-approved-substance category at that time. Sporting prohibition is an anti-doping rule, not a clinical assessment of benefit. [11] [9]

AOD-9604 should not be presented as ‘growth hormone without the risks’. In the obese-mouse study, it behaved differently from hGH in measured glucose and hGH-receptor assays, and the short human studies did not show a treatment-group increase in IGF-1. Those are limited observations, not evidence that every known or unknown hGH-related risk has been excluded, nor evidence of therapeutic equivalence to an approved hGH medicine. [2] [6]

It also cannot be treated as an evidence-based alternative to a registered weight-management medicine simply because both are discussed in the context of body weight. The main AOD-9604 obesity trial failed its weight-loss endpoint, whereas medicines are approved only in specified formulations and indications after regulator review. Any comparison should begin with the exact approved product, indication, population, trial duration and outcome—not with internet marketing language or untested combinations. [4] [5] [8]

First identify the model. A statement that AOD-9604 increased fat oxidation, glycerol or β3-AR RNA is a rodent finding from a defined experiment; it is not a demonstrated patient outcome. A statement that it ‘does not raise IGF-1’ comes from relatively short historical studies and does not establish endocrine safety across products, doses, routes or years of use. [2] [3] [6]

Then look for the comparison and endpoint. The most decision-relevant human efficacy study compared AOD-9604 with placebo in 502 randomised participants and did not meet its 12-week weight-loss endpoint. Claims based on a favourable subgroup or on the preceding smaller study must be read after, not instead of, that result. There is no validated combined protocol for AOD-9604 with other peptides or medicines in the sources reviewed here. [4] [5]

Finally, separate a chemical name from a pharmaceutical product. Published studies concern defined investigational material and specified trial protocols. They do not verify the identity, concentration, sterility, impurities, stability, route suitability or clinical performance of an online, imported or research-supplier vial. [1] [8] [10]

Is AOD-9604 an approved medicine in Australia?

No approved AOD-9604 medicine was identified in the regulator records reviewed. AOD-9604 is scheduled in the Australian Poisons Standard, but scheduling is a control on availability, not ARTG registration. The TGA’s 2026 court material identified advertised AOD9604 creams and injections as goods not entered in the ARTG during the relevant period. [7] [8] [12]

Is AOD-9604 the same as human growth hormone?

No. It is a synthetic analogue of a short C-terminal hGH segment, not full-length hGH. In a mouse/cell experiment it did not compete for the hGH receptor, but that does not establish a complete human mechanism or make it risk-free. [1] [2]

Did AOD-9604 work for weight loss in people?

The best-documented larger study, the 536-enrolled/502-randomised OPTIONS trial, did not find a statistically significant difference in weight loss versus placebo at its primary 12-week endpoint. Earlier smaller and incompletely reported studies are not sufficient to reverse that conclusion. [4] [5]

Does a vial marked ‘research use only’ or ‘peptide’ have the same status as the study drug?

No. The published evidence does not authenticate commercial vials. The TGA warns that unapproved imported peptide products may be poorly labelled and cannot reliably be checked for contents, concentration, sterility or contaminants; FDA also highlights peptide-characterisation, impurity and possible immunogenicity concerns for compounded AOD-9604. [8] [10]

Is AOD-9604 permitted in competitive sport?

No under the current WADA list: it is specifically named as a growth-hormone fragment prohibited at all times. Athletes should seek sport-specific advice through their anti-doping organisation rather than infer permission from a product’s marketing. [9]

The human efficacy record is limited by incomplete reporting: the pivotal OPTIONS results are available through a sponsor announcement rather than a full peer-reviewed paper, and earlier positive-suggesting data are abstract-level or retrospective summaries. The principal animal work used mouse models and experimental routes that do not establish human benefit or safety. Short studies and selected antibody testing cannot settle long-term systemic, injectable, topical, high-dose or combination safety. The sources reviewed did not identify a validated clinical protocol, a confirmed direct human molecular target, or an approved AOD-9604 formulation; this record therefore intentionally provides no administration, reconstitution, storage or blending guidance.

1. [1] Detection and in vitro metabolism of AOD9604. Validated LC-MS/MS detection and in-vitro incubation/metabolite characterisation in serum and urine.
2. [2] Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. 14-day mini-osmotic-pump study in obese ob/ob and lean C57BL/6J mice, plus hGH-receptor binding and proliferation assays in transfected cells.
3. [3] The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. 14-day chronic intraperitoneal treatment in obese mice and β3-adrenergic-receptor knockout mice, with an acute experiment and adipose RNA measures.
4. [4] Metabolics obesity drug – Phase 2B clinical trial results (OPTIONS Study). Australian multicentre, double-blind, randomised, placebo-controlled trial: 536 enrolled and 502 randomised adults with obesity; 24-week oral treatment after a diet/exercise run-in.
5. [5] FDA Pharmacy Compounding Advisory Committee briefing materials: AOD-9604-related bulk drug substances. FDA review of published, sponsor-supplied and regulatory information for proposed compounding uses.
6. [6] Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans. Narrative summary of six sponsor-funded randomised, double-blind, placebo-controlled studies, including oral exposure up to 24 weeks.
7. [7] Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026. National scheduling instrument; not a clinical study.
8. [8] TGA warning on the risks of importing unapproved peptide products. Consumer safety and importation advisory; not a clinical study.
9. [9] World Anti-Doping Code International Standard: Prohibited List 2026. International prohibited-substances standard; not a clinical study.
10. [10] Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA assessment of nominated bulk drug substances for compounding policies; not a controlled clinical trial.
11. [11] WADA statement on substance AOD-9604. Regulatory status statement; not a clinical study.
12. [12] TGA BioV8 concise statement. Concise statement concerning advertising allegations; not a clinical study.